Table 1.
Patient characteristics.
| Variable | N (%) | |
|---|---|---|
| All patients (N = 57) | ||
| Age | ||
| Median (range) | 58.5 (35–75) | |
| Gender | ||
| Male | 27 (47.4) | |
| Female | 30 (52.6) | |
| Tumor types | ||
| Gastric cancer | 15 (26.3) | |
| Colon cancer | 3 (5.3) | |
| Sarcoma | 4 (7.0) | |
| Hepatocellular carcinoma | 1 (1.7) | |
| Neuroendocrine carcinoma | 1 (1.7) | |
| Melanoma | 33 (57.9) | |
| Prior lines of chemotherapy | ||
| 1 regimen | 25 (43.8) | |
| 2 regimens | 18 (31.6) | |
| ≥3 regimens | 14 (24.6) | |
| Metastatic site | ||
| Liver | 24 (42.1) | |
| Prior anti-PD1 therapy | 35 (61.4) | |
| Melanoma patients (N = 33) | ||
| Prior anti–PD-L1 | 33 (100.0) | |
| Prior anti-CTLA4 therapy | 0 | |
| Prior RAF inhibitor | 6 (18.1) | |
| Prior lines of chemotherapy | ||
| 1 regimen | 14 (42.4) | |
| 2 regimens | 19 (57.6) | |
| LDH expression | ||
| ≤ULN | 5 (15.2) | |
| >ULN to ≤2x ULN | 10 (30.3) | |
| >2x ULN | 18 (54.5) | |
| Stage, M category (AJCC 8th) | ||
| M1a | 4 (12.1) | |
| M1b | 5 (15.1) | |
| M1c | 21 (63.8) | |
| M1d | 3 (9.0) | |
| Best response to prior anti–PD-1/L1 | ||
| CR or PR | 4 (12.1) | |
| SD | 16 (48.5) | |
| PD | 13 (39.4) | |
| BRAF mutation | 3 (9.0) | |
| NRAS mutation | 6 (18.2) | |
| Brain metastasis | 3 (9.0) | |
| Melanoma subtypes | ||
| Acral | 10 (30.3) | |
| Cutaneous | 11 (33.3) | |
| Mucosal | 11 (33.3) | |
| Unknown | 1 (3.1) | |
| Stage IV melanoma | 33 (100.0) | |